CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Uaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Total revenue	$ 7,572,103	$ 6,800,077
Operating costs and expenses:
Cost of pharmaceuticals sold	2,415,132	1,824,465
Medical consumables	872,592	780,272
Salaries and benefits	1,539,079	1,027,089
Office supplies	389,360	210,500
Vehicle expenses	81,935	31,009
Utilities expenses	196,316	178,979
Operating leases expense	28,163	26,737
Advertising and promotion expenses	25,360	45
Professional fee	41,288
Depreciation and amortization	538,224	381,849
Total operating costs and expenses	6,127,449	4,460,945
Earnings from operations before other income and income taxes	1,444,654	2,339,132
Other income	(231,475)	(310,010)
Earnings from operations before income taxes	1,213,179	2,029,122
Income tax	255,792	581
Net income	957,387	2,028,541
Less: net income attributable to non-controlling interests	288,799	608,562
Net income attributable to the Company	668,588	1,419,979
Comprehensive income:
Foreign currency translation adjustment	524,928	833,086
Foreign currency translation adjustment attributable to non-controlling interests	170,771	249,159
Foreign currency translation adjustment attributable to the Company	354,157	583,928
Comprehensive income	1,482,315	2,861,628
Less: Comprehensive income attributable to non-controlling interests	459,570	857,721
Comprehensive income attributable to the Company	$ 1,022,745	$ 2,003,907
Basic and diluted earnings per share	$ 0.0446	$ 0.0955
Weighted average number of shares outstanding	14,975,000	14,871,111
Pharmaceuticals [Member]
Revenue:
Total revenue	$ 2,814,548	$ 2,708,046
Patient services [Member]
Revenue:
Total revenue	$ 4,757,555	$ 4,092,031